An overview of sulfonamide-based conjugates: Recent advances for tuberculosis treatment

Cauê Benito Scarim; Fernando Rogério Pavan

doi:10.1002/ddr.21913

An overview of sulfonamide-based conjugates: Recent advances for tuberculosis treatment

Drug Dev Res. 2022 May;83(3):567-577. doi: 10.1002/ddr.21913. Epub 2022 Jan 18.

Authors

Cauê Benito Scarim¹, Fernando Rogério Pavan²

Affiliations

¹ Department of Cell and Molecular Biology, University of Mississippi Medical Center (UMMC), Jackson, Mississippi, USA.
² School of Pharmaceutical Sciences, Sao Paulo State University (UNESP), Araraquara, Sao Paulo, Brazil.

PMID: 35040503
DOI: 10.1002/ddr.21913

Abstract

In 2019, tuberculosis (TB) caused approximately 1.4 million deaths around the world. TB is an infectious respiratory disease mainly caused by Mycobacterium tuberculosis. The lack of new drugs to treat drug-resistant strains is a principal factor for the continuous slow rise in TB infections. Sulfonamides are active moieties in various drugs used against several sicknesses, including TB. Our aim is to aid the development of new TB treatments and drugs by describing recent improvements (2011-2021) to sulfonamide-based compounds.

Keywords: Mycobacterium tuberculosis; new drugs; sulfonamide analogues.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Antitubercular Agents / pharmacology
Antitubercular Agents / therapeutic use
Humans
Mycobacterium tuberculosis*
Sulfonamides / therapeutic use
Tuberculosis* / drug therapy
Tuberculosis* / microbiology

Substances

Antitubercular Agents
Sulfonamides